

CRISPR and Preventative Medicine: How Gene Editing Could Change Disease Risk

Vanshika Sathish

Systems Thinkers in STEM Ambassador at Institute for Systems Biology

September 2026

Abstract

CRISPR is one of the biggest scientific breakthroughs in modern biology because it gives scientists the ability to edit DNA in a very precise way. DNA controls how our bodies grow, develop, and function, and mistakes in DNA can cause many serious diseases. In the past, most medical treatments focused on helping people after symptoms appeared, which often meant the disease had already done damage. This can lead to worse health outcomes, higher medical costs, and more stress on patients and families. With new gene editing tools like CRISPR, scientists are starting to explore treatments that can target the root cause of diseases before symptoms begin. This could change healthcare by shifting it toward prevention rather than reaction.

The purpose of this project is to understand how CRISPR works and to explore how it could be used in preventative medicine. I want to explain these ideas in a way that students and community members can understand, even if they do not have a science background. CRISPR is often described in complicated terms, so part of my goal is to break it down into simple language. I will also look at how CRISPR fits into systems medicine, which studies how different parts of healthcare connect. This includes genetics, biotechnology, clinical research, healthcare providers, ethics, laws, and patient needs. These areas all affect how and when CRISPR can be used in real life.

For this project, I selected four main sources. The first is an ISB report describing the first trial where CRISPR was used to engineer T-cells to help cancer patients. The second is an update from the Innovative Genomics Institute that explains both the exciting progress and the major challenges in CRISPR clinical trials around the world. The third is a scientific review posted on the National Library of Medicine that describes how CRISPR is being used in clinical research, including information about safety problems, delivery systems, and current trials. The fourth source is a detailed article from Cambridge University Press about how CRISPR gene therapy is moving forward, including the first FDA-approved CRISPR treatment for sickle cell disease.

By studying these sources, I hope to answer the question: How could CRISPR gene editing be used to prevent disease, and what factors determine whether it can be used safely and responsibly? This project will help me improve my skills in scientific reading, systems thinking, and clear communication. It may also help others understand why CRISPR is such an important technology for the future of medicine!

Introduction to CRISPR and Preventative Medicine

Understanding how CRISPR could be used in preventative medicine starts with understanding why prevention is so important in the first place. Today, many diseases are treated only after symptoms appear, which means that the illness has already had time to damage cells, tissues, and organs. For example, many genetic disorders do not show clear signs until they have progressed, even though the problem began at the DNA level long before. This delayed detection is a common issue in healthcare, and it can lead to more severe problems, higher medical bills, and lower chances of recovery. Because of this, doctors and scientists are now looking for ways to identify and treat diseases earlier. CRISPR offers a possible answer to this problem because it can target the source of a disease before the symptoms begin.

CRISPR is a gene editing tool that scientists discovered by studying how bacteria protect themselves from viruses. Bacteria use CRISPR to recognize and cut viral DNA, which stops infections before they can spread. Scientists realized they could use this system to edit DNA in other organisms, including humans. The main idea behind CRISPR is simple: it uses a guide RNA to locate a specific DNA sequence, and the Cas9 protein cuts that DNA at the chosen spot. After this cut, the cell repairs the DNA, and scientists can use this repair process to delete, add, or change genes. Even though CRISPR sounds complex, the basic concept is like using scissors and a ruler to cut and fix a tiny piece of text inside a long instruction manual.

The possibility of using CRISPR in preventative medicine is exciting because many diseases start with small DNA mistakes. If these mistakes could be fixed early, the disease might be avoided completely. Some genetic conditions are caused by a single mutation, so CRISPR could correct that one error before it leads to symptoms. There is also interest in using CRISPR to lower the risk of more common diseases, such as heart disease or certain cancers, by adjusting genes that influence risk levels. However, this idea is still in early stages, and scientists need much more research to know what is safe and ethical.


Even though CRISPR has great potential, it is important to understand its challenges. Editing genes in living people is not simple, and there are risks such as off-target effects, which happen when CRISPR cuts the wrong part of the DNA. There are also concerns about fairness, cost, and who would have access to these treatments. Because of this, CRISPR must be studied carefully in clinical trials. These trials help scientists test safety, check effectiveness, and figure out the best ways to deliver CRISPR into cells. Some clinical trials have already shown success, such as the CRISPR treatment for sickle cell disease. These results show that gene editing can work in real humans and not just in the lab.

This introduction sets the foundation for the rest of the paper. In the next pages, I will explain how CRISPR works in more detail, describe important clinical trials, and explore how this technology could shape the future of preventative medicine.

How CRISPR Works

CRISPR is a gene editing tool that lets scientists change DNA in a very exact way. To understand how it works, it helps to look at the two main parts involved. The first part is the guide RNA, which is like a small piece of code that searches for a specific DNA sequence inside a cell. Scientists design the guide RNA to match the gene they want to target. The second part is Cas9, which is a protein that acts like scissors. Once the guide RNA finds the right spot in the DNA, Cas9 makes a cut at that location.

After the DNA is cut, the cell tries to repair it. This repair step allows scientists to make changes. CRISPR can be used to turn off a gene, fix a mutation, or add a new piece of DNA. For example, if a disease is caused by a harmful mutation, CRISPR could correct it before symptoms appear.



An overview of the CRISPR-Cas9 gene-editing process, illustrating how the Cas9 protein and guide RNA complex identify and cut specific DNA sequences. Adapted from "CRISPR: Engineering a Better Future through Genetics," SCOR, 2023.

This image helps show how the guide RNA finds the target and how Cas9 cuts the DNA.

One reason CRISPR became so important in science is that it is faster and easier to use than older gene editing tools. Before CRISPR, scientists used zinc finger nucleases and TALENs, which were harder to design and took longer to make. With CRISPR, researchers can change the guide RNA to edit almost any gene. This makes it much more flexible and useful for studying diseases and testing treatments.

However, CRISPR is not perfect. Sometimes it can cut the wrong part of the DNA. These mistakes are called off-target effects, and they can cause problems if healthy genes are damaged. Scientists are working to make CRISPR more accurate and safe by improving the guide RNA and testing new versions of Cas9 that are less likely to make mistakes.

Understanding how CRISPR works helps explain why it is being studied in clinical trials today. If scientists can safely edit genes in living cells, it could lead to new ways to prevent diseases before they start. In the next section, I will explain how CRISPR is being used in real patients and what early trials have shown.

CRISPR in Clinical Trials

Now that CRISPR has been tested and improved in labs, scientists are starting to use it in real medical treatments through clinical trials. A clinical trial is a research study that tests a treatment in human patients. These trials are very important because they help doctors understand if a treatment is safe, how well it works, what dose to use, and what risks might appear. CRISPR trials are still very new, but some of them have already shown results that scientists never thought would be possible this early.

One of the biggest successes in CRISPR trials so far is the treatment for sickle cell disease and transfusion-dependent beta thalassemia. These conditions are serious genetic blood disorders that affect the hemoglobin in red blood cells. In late 2023 and early 2024, a CRISPR-based treatment was approved for these diseases. This was a major milestone because it was the first time the FDA approved a CRISPR therapy for real use in medical practice. The treatment involves editing a person's own stem cells to correct the problem in their blood. After the edited cells are put back into the patient, they begin producing healthy red blood cells. Many patients in the trials showed strong improvements and no longer needed blood transfusions.

Another big moment in 2025 was the first personalized CRISPR treatment made specifically for one infant with a rare genetic disease. Doctors and scientists worked together to design a custom CRISPR therapy in only six months. This treatment was made to fix the exact mutation that caused the baby's condition. This is important because it shows that personalized gene editing could be possible in the future. Instead of using the same treatment for every patient, doctors could design solutions that match each person's DNA.


CRISPR trials are also expanding into new areas. Some trials focus on lowering cholesterol levels by editing genes in the liver. Others target eye diseases that cause blindness or test treatments for certain cancers. There are also trials for rare genetic disorders that previously had no cure. These early results give scientists hope that CRISPR may be useful not only for treating diseases but also for preventing them before symptoms start.

Even though the progress is exciting, there are challenges. CRISPR treatments are very expensive right now because they require special equipment, trained scientists, and long hospital stays. Many companies working on CRISPR research have faced funding cuts, which slows down progress. There are also safety concerns that must be studied carefully. Clinical trials help researchers understand side effects, long-term risks, and how the body reacts to edited cells.

Overall, CRISPR clinical trials are giving us valuable information about what is possible and what still needs improvement. They are an important step toward using CRISPR in preventative medicine. The next pages will discuss each of the main sources and what they show about CRISPR's development.

Source 1: “In First-of-Its-Kind Trial, Scientists Use CRISPR to Treat Cancer” (Institute for Systems Biology)

The first source I reviewed comes from the Institute for Systems Biology (ISB) and reports a major milestone in CRISPR medicine. This article explains how scientists used CRISPR to edit a patient’s T-cells so they could better recognize and attack cancer cells. This trial was the first time CRISPR was used to replace a gene inside immune cells for treating cancer. This research, originally detailed in the scientific study "Non-viral precision T cell receptor replacement for personalized cell therapy" (Foy et al. 687), is important because it shows CRISPR being used safely in real patients, not just in lab experiments.



OpenAI. *CRISPR-Engineered T-Cell Therapy Process*. ChatGPT, 2026. AI-generated image.

T-cells are immune cells that help the body defend itself. Some T-cells can naturally recognize cancer cells, but usually there are not enough of them to stop the cancer from growing. In this study, scientists identified the specific T-cells in each patient that already knew how to detect their tumor. They then used CRISPR to edit many more T-cells so they had the same cancer-recognizing ability. After the editing was complete, the new T-cells were placed back into the patient so they could attack the tumor more effectively.

A major innovation in this study was the method used to insert new instructions into the cells. Older techniques used viruses to deliver new genes, which could take a long time and be costly. With CRISPR, scientists were able to “knock in” the needed genes without using viruses. This made the process faster and easier, which is important if this treatment becomes more widely available in the future. ISB President Dr. Jim Heath explained that this approach is a huge step forward for personalized cancer treatment.

The early trial included 16 patients, and the main goal was to test safety. The results showed that CRISPR-edited T-cells did not cause severe side effects and were able to travel to the tumors. This means the cells worked the way scientists expected. Although the trial was not designed to cure cancer, it proved that CRISPR can safely edit immune cells in humans. This success provides a strong foundation for more advanced studies that could help improve cancer treatment outcomes.

This source also connects to preventative medicine. Even though this trial focused on treatment instead of prevention, it shows how CRISPR could eventually help stop diseases earlier. If T-cells can be edited to detect cancer sooner, doctors may be able to treat patients before tumors grow and spread. This study helps us understand what CRISPR can do in living humans and what challenges researchers still need to solve.

Source 2: “CRISPR Clinical Trials: A 2025 Update” (Innovative Genomics Institute)

The second source I reviewed is from the Innovative Genomics Institute (IGI) and gives an overview of the progress and challenges in CRISPR clinical trials during 2025. The article explains how CRISPR treatments are expanding into real medical care, but it also shows that financial and political issues are slowing down research. This source is helpful because it shows how science and healthcare depend on funding, companies, and government support.

One major highlight from the article is the success of Casgevy, the first CRISPR treatment approved for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). Casgevy edits a patient’s own stem cells to help them make healthy blood. After approval, more than 50 treatment centers opened across the United States, Europe, and the Middle East. This shows that CRISPR treatments are becoming more available. The source also explains that paying for Casgevy is difficult, but companies are working with Medicaid and the UK National Health System to help cover the cost.

Another important event discussed in the article is the first personalized CRISPR therapy made for a single infant with a rare genetic disease. A team of scientists created this treatment in just six months. This is a huge step because it shows that custom gene editing may be possible in the future for rare diseases with no cure. It also suggests that CRISPR could someday allow doctors to design treatments specifically for an individual’s DNA.

The source also describes new CRISPR trials for more common diseases, including heart disease. Some trials focus on editing genes in the liver to lower cholesterol. The article says that liver editing is working well because the liver is easier to target with CRISPR. The source also mentions trials for cancers, eye diseases that cause blindness, infections, and autoimmune disorders. This shows that CRISPR could affect many areas of medicine, not just rare genetic diseases.

Even though the scientific progress is exciting, the article explains that the CRISPR field is facing problems. Many biotech companies have less funding because investors want quick results. As a result, companies are starting fewer new research projects, and some have laid off workers. This slows down how fast new treatments can be developed.

The article also warns that the US government has cut funding for scientific research, including programs that support biology labs and STEM education. These cuts could slow down the development of new CRISPR tools and reduce the number of clinical trials in the future. Without strong funding, even the best scientific ideas may not move forward.

Overall, this source shows that CRISPR progress depends on more than just science. It also depends on money, support, and long-term planning. For CRISPR to be used in preventative medicine, research programs need stable funding and strong public investment.

Source 3: “Clinical Applications of the CRISPR/Cas9 Genome-Editing System: Delivery Options and Challenges in Precision Medicine” (National Library of Medicine)

The third source I reviewed is a scientific article that explains how CRISPR/Cas9 is being used in clinical trials and what challenges still exist. This source is more technical than the others, but it helped me understand the real-world details behind gene editing. It focuses on the medical uses of CRISPR, different delivery methods, and the problems researchers must solve before CRISPR becomes common in hospitals.

One important idea from the article is that CRISPR is being tested for many illnesses, such as cancer, blood disorders, immune problems, and eye diseases. The article lists several trials, including ones where CRISPR is used to treat sickle cell disease by editing the BCL11A gene. It also describes early cancer trials where T-cells are edited to help the immune system fight tumors more effectively. These examples show that CRISPR is not just a lab tool but something that is already being tested in real patients.

The article also explains the difference between ex vivo and in vivo editing.

- Ex vivo editing means cells are taken out of the body, edited in a lab, and then returned to the patient. This method is safer because scientists can check the edited cells before using them. Many blood-related trials use this approach.

- In vivo editing means CRISPR is delivered directly into the patient. This is necessary for diseases involving organs like the liver or the eye, where cells cannot easily be removed. However, in vivo editing is harder because CRISPR must reach the exact cells without causing damage.

Another major topic in the article is the different delivery systems used to get CRISPR into cells. These include viral vectors, lipid nanoparticles, and other nanotechnology-based methods. Viral vectors can carry a lot of genetic material but may cause immune reactions. Lipid nanoparticles are safer but can sometimes be less effective. Finding the right delivery system is one of the biggest challenges in CRISPR medicine, especially for in vivo treatments.

The article also discusses off-target effects, which happen when CRISPR cuts the wrong part of the DNA. This can create unwanted mutations, so researchers are working to make CRISPR more accurate. They are testing improved versions of Cas9 and better-designed guide RNAs. The article also mentions newer tools like base editing and prime editing, which can change DNA without cutting it. These tools may help reduce off-target effects in the future.

Overall, this source shows that CRISPR has huge potential in medicine, but there are still important safety and delivery problems to solve. This information connects to preventative

medicine because it explains why CRISPR must be made very safe before it can be used to prevent diseases early in life.

More Findings from Source 3: Key Challenges in CRISPR Medicine

Source 3 also goes into detail about the biggest obstacles that stop CRISPR from being used more widely in medical treatment. Even though CRISPR has shown promising results in many trials, scientists still need to solve several safety and delivery issues before CRISPR can be used for preventative medicine. These challenges explain why CRISPR is mostly used in early clinical trials and not yet in regular healthcare.

One of the main problems the article describes is the delivery challenge. CRISPR needs to reach the right cells in the body for the treatment to work, but this is harder than it sounds. The human body has many types of cells, and each type has different structures, sizes, and locations. In *ex vivo* editing, delivery is easier because scientists can directly add CRISPR to cells in the lab. But for *in vivo* editing, CRISPR has to travel through the body without getting destroyed by the immune system. The source explains that researchers are experimenting with viral vectors, lipid nanoparticles, and other nanotechnology tools to improve delivery efficiency.

The article also explains why delivery methods must be safe. If a delivery system sends CRISPR into the wrong cells, it could harm healthy tissues. For example, if CRISPR reaches cells where editing is not needed, it might cause random DNA changes. That is why scientists need delivery systems that target the correct cells and avoid off-target tissues.

Another major challenge the article discusses is the off-target effect, where CRISPR cuts DNA in the wrong place. While CRISPR is designed to be precise, it is not perfect. Off-target cuts can damage genes that are important for normal cell function. This could lead to dangerous side effects, including mutations or cancer. Because of this, scientists are developing more accurate versions of Cas9 and better-designed guide RNAs to lower the risk of off-target cuts. They are also testing new editing approaches like base editing and prime editing, which can change DNA without making a double-stranded cut.

The article also talks about immune system reactions. Because CRISPR uses proteins from bacteria, the human body might recognize Cas9 as something foreign and attack it. This can make treatments less effective or cause inflammation. Researchers are studying how to prevent strong immune responses by adjusting doses or changing delivery methods. They are also testing smaller versions of Cas proteins that may cause fewer immune reactions.

Another challenge mentioned is editing multiple genes at once. Some diseases involve more than one gene, but CRISPR usually focuses on one gene at a time. Editing multiple genes increases the chances of mistakes and makes delivery harder. The article explains that scientists are working on new CRISPR systems, such as Cas12a and Cas13, that might edit multiple genes more safely.

Overall, this part of the source helps show why CRISPR is still mostly used in trials. Even though the science is moving forward, researchers must solve these safety and delivery issues before CRISPR can be used in preventative care for large populations. This information is

important because preventative treatment must be extremely safe, especially if used before symptoms appear.

How Source 3 Connects to Preventative Medicine and Systems Thinking

Source 3 does not focus only on what CRISPR can do right now. It also helps explain what needs to happen before CRISPR can be used as a preventative tool. Preventative medicine means stopping a disease before symptoms show up. For CRISPR to fit into that system, it must be reliable, safe, and predictable. The article makes it clear that CRISPR is powerful, but it is still early in development. Understanding these limitations is important because preventative treatments require extremely low risk.

One way this source connects to preventative medicine is by showing that certain diseases might be prevented if researchers can edit genes before damage occurs. For example, some genetic diseases like sickle cell disease or beta-thalassemia start affecting the body early in life. If CRISPR editing becomes safer, doctors may one day be able to correct these mutations before they cause long-term health problems. This could reduce hospitalizations, improve quality of life, and lower long-term healthcare costs. The article supports this by describing clinical trials where edited cells continue working in the body after treatment, showing that one-time edits can last a long time.

The source also connects to systems medicine by showing how different parts of the healthcare system need to work together. CRISPR technology is not just about biology. It requires scientists who study genetics, doctors who treat patients, engineers who design delivery systems, and policy experts who create safety guidelines. All of these parts must work together to develop safe preventative treatments. For example, if researchers figure out how to deliver CRISPR safely but doctors do not have training or resources to use it, the technology will not reach patients. The source shows that CRISPR medicine depends on more than just scientific progress.

Another important systems connection is the role of regulation. Preventative treatments need strict safety guidelines because they could be used on healthy people or on patients before symptoms appear. Source 3 explains that off-target effects, delivery challenges, and immune reactions must be solved before CRISPR can be approved for widespread preventative use. Regulatory agencies like the FDA will need strong evidence that CRISPR does not cause long-term harm. This adds another layer to the system, because regulators, scientists, and healthcare providers must communicate clearly and share accurate data.

The article also helps show why public trust is a key part of the system. If people worry about CRISPR being unsafe, they may be afraid to use gene editing even if it becomes safe in the future. Ethical questions also play a big role. Preventative gene editing raises concerns about who gets access, how early in life editing should happen, and how to avoid unfair advantages. These ideas show that preventative CRISPR treatments are not only scientific decisions but also social and ethical ones.

Overall, Source 3 helps explain how CRISPR could fit into a preventative healthcare system, but also why we are not ready for that yet. The challenges described in the article show that scientists

must improve accuracy, delivery methods, and safety before preventative gene editing becomes realistic. Understanding these challenges now helps guide future research.

Source 4: “Advancing CRISPR Genome Editing into Gene Therapy Clinical Trials: Progress and Future Prospects” (Cambridge University Press)

The fourth source I reviewed was published by Cambridge University Press and focuses on how CRISPR is moving forward in clinical trials and what the future might look like for gene editing. This source is important because it explains not only where CRISPR is right now, but also what improvements are being made to make it safer, more accurate, and more widely available. It also talks about the first FDA approval of a CRISPR-based therapy, which is a major moment in medical history.

One of the biggest points in the article is the approval of Casgevy, which I mentioned earlier is the first CRISPR therapy officially allowed for sickle cell disease. This approval shows that CRISPR treatments can meet strict safety and effectiveness rules. It also proves that gene editing can work on a real medical condition, not just in research labs. Casgevy edits a patient’s stem cells so they can produce healthy red blood cells. The article suggests this is just the start and that more CRISPR-based treatments could be approved in the future.

The source also explains that CRISPR is being tested for many different diseases. These include cancers, HIV, heart disease, and rare genetic conditions. Each trial uses CRISPR in different ways. For example, in cancer trials, immune cells are edited to attack tumors more effectively. In HIV trials, researchers try to remove or block the receptor that HIV uses to enter cells. These examples show how flexible CRISPR is and how it can be adjusted for many health problems.


Another important topic in the article is the development of newer editing tools, such as base editing and prime editing. Unlike traditional CRISPR/Cas9, these tools do not make double-stranded cuts in DNA. This reduces the chances of unwanted mutations. Because they are more precise, these tools may have fewer side effects and could be safer for patients. This is especially important for preventative medicine, where safety must be extremely high because the treatment might be used before symptoms even appear.

The article also talks about ongoing challenges that need to be solved. These include off-target effects, where CRISPR cuts the wrong part of the DNA, and delivery problems, which make it hard to get CRISPR into the correct cells. The article also highlights ethical concerns, especially when gene editing involves embryos or germline cells. Editing these cells could pass genetic changes to future generations, so the article stresses that strong safety guidelines and ethical rules are necessary.

Overall, this source from Cambridge University Press shows both the progress and the responsibility that comes with CRISPR. It proves that CRISPR has already changed medicine by achieving FDA approval, but it also reminds us that careful testing and strong safety standards are needed before CRISPR can be used widely or for preventative treatments.

How Source 4 Shows the Future of CRISPR in Preventative Medicine

Source 4 provides important insight into how CRISPR could be used in the future, especially in preventative medicine. The article explains that gene editing is becoming more precise and safer through new tools like base editing and prime editing. These improvements matter because preventative treatments must have very low risk. If CRISPR is eventually used to prevent diseases before symptoms begin, it needs to be extremely accurate. The source helps show how scientists are moving closer to that goal.



OpenAI. *Preventative Medicine Model*. ChatGPT, 2026. AI-generated image.

One of the main ideas from this source is that CRISPR treatments are becoming more realistic now that the first therapy, Casgevy, has been approved. This proves that gene editing can work safely in humans and pass strict medical standards. This step is important for prevention because it builds trust in CRISPR technology. If people see that gene editing can treat diseases like sickle cell safely, they may be more open to using CRISPR earlier in life to prevent disease in the first place.

The article also explains how next generation editing tools could help with prevention. Base editing can fix single DNA letters without cutting the DNA completely, which makes it less risky. Prime editing is even more flexible and can change larger DNA sections with high precision. These tools may one day correct disease causing mutations before they lead to serious health problems. For example, conditions like cystic fibrosis, Tay-Sachs disease, or certain heart disorders might be prevented if the mutation is corrected early enough.

Another important idea from this source is the need for careful testing. The article emphasizes that even though CRISPR is powerful, scientists still need to understand long-term effects. Preventative treatments would likely be done on younger patients or even before birth, so safety must be extremely high. This means more research, stronger rules, and clear guidelines. The source explains that regulators, scientists, and medical teams must work together to make sure CRISPR is used responsibly.

Source 4 also connects to systems thinking because it shows how different parts of the healthcare system must interact. It mentions clinical trials, government approvals, ethics committees, researchers, and the public. All of these groups must communicate and make decisions about how CRISPR should be used. Preventative medicine especially relies on this system because it affects people who are not sick yet, which makes decision-making more complicated.

Ethics is another key part of the system. The article discusses concerns about germline editing, which affects future generations. Preventative treatments must balance the benefits of stopping disease early with the responsibility of avoiding harmful or unfair genetic changes. The article shows that ethics is not separate from science. It is part of the entire system of developing CRISPR.

Overall, Source 4 shows that CRISPR has huge potential for the future of preventative medicine, but scientists need to continue improving accuracy and safety. It highlights progress with real clinical trials and new editing technologies while also showing that ethical and safety challenges must be addressed. This source helps explain not only what CRISPR can do now but also what it might eventually achieve.

Connecting All Four Sources Together

After reviewing all four sources, a clear pattern appears about where CRISPR stands today and what it might become in the future. Each source focuses on different areas of CRISPR research, but together they show the full story: CRISPR is powerful, still developing, and slowly becoming safe enough to consider for preventative medicine. These sources also show how science, medicine, funding, and ethics are all connected when it comes to gene editing.

Source 1 from the Institute for Systems Biology shows how CRISPR can help treat cancer by editing T-cells outside of the body and then placing them back into the patient. This demonstrates that CRISPR can work safely in humans and can help the immune system become stronger. This is important because it proves CRISPR can be used in real patients without causing major harm. It also shows how personalized medicine might work in the future.

Source 2 from the Innovative Genomics Institute shows the larger picture of CRISPR clinical trials in 2025. It includes success stories like Casgevy and the first personalized CRISPR treatment ever made for a single infant. It also explains the challenges caused by limited funding and slow progress in some companies. This source helps explain the system around CRISPR, not just the science. Even if the technology works, it cannot help patients unless funding, policy, and public support are all strong enough.

Source 3 is the most scientific and explains delivery methods, off-target effects, and safety issues. It goes into detail about ex vivo editing and in vivo editing and shows why delivery is one of the biggest problems CRISPR still has. This source helps explain why CRISPR is not ready for widespread preventative use yet. If the delivery system is not perfect, CRISPR could cause accidental damage in healthy cells. Preventative medicine requires extremely high safety levels, so this source helps show what still needs to be improved.

Source 4 from Cambridge University Press explains how CRISPR is improving and how new tools like base editing and prime editing could make gene editing safer and more accurate. It also shows the importance of ethics, long-term safety testing, and strong regulation. This source connects the scientific improvements to the future of medicine and helps explain how CRISPR might eventually prevent diseases before symptoms appear.

When these four sources are put together, they create a complete picture. We can see where CRISPR started, what trials have been done, what challenges still exist, and what might be

possible in the future. All of the sources agree that CRISPR has great potential but must be improved before it is used in preventative medicine. They also show that CRISPR is part of a large system involving research labs, hospitals, funding programs, government agencies, and the public. This system needs to work together for CRISPR technology to be safe and successful.

Overall, the sources support the idea that CRISPR could eventually change how we treat and prevent disease, but only if safety challenges, delivery problems, and ethical issues are solved first. These sources give strong evidence that CRISPR is moving in the right direction and could one day be used to prevent genetic diseases rather than only treating them after symptoms appear.

Conclusion: What CRISPR Could Mean for the Future of Preventative Medicine

After reviewing all the sources and researching how CRISPR works, it is pretty clear that gene editing has the potential to change the future of medicine. CRISPR is already being used in clinical trials, and in some cases, patients have experienced life-changing results. The approval of Casgevy shows that CRISPR can work safely in humans, and other trials show that CRISPR can help treat cancer, rare genetic diseases, and possibly more common conditions like heart disease. These achievements suggest that CRISPR might one day be used not only to treat diseases but also to prevent them before symptoms even appear.

However, the research also shows that CRISPR is not ready for widespread preventative use yet. There are still major challenges involving delivery, accuracy, off target effects, and safety. Preventative medicine requires extremely high levels of reliability, especially if treatment is used on younger patients or edited cells that will last a lifetime. Source 3 explained that CRISPR delivery systems still need improvement, and off target cuts must be reduced before CRISPR can be used safely in healthy people. Source 4 showed that new tools like base editing and prime editing might solve some of these problems by allowing more precise changes without cutting the DNA completely.

The sources also show that CRISPR is part of a much bigger system. It involves scientists, doctors, engineers, companies, governments, and patients. Clinical trials require large amounts of funding, and companies need support to develop new treatments. The cuts in scientific research funding discussed in Source 2 show how financial problems can slow progress even when the science is ready to move forward. Ethical questions also play a major role. Society must decide when gene editing should be allowed, who gets access to it, and how to protect future generations from unintended effects.

Even though CRISPR still has challenges, it is clear that the technology is moving in a positive direction. Every year, researchers solve new problems and discover safer ways to edit DNA. Many scientists believe that in the future, CRISPR may help prevent genetic illnesses early in life, reduce the need for long term treatments, and lower healthcare costs by stopping disease before it starts. For chronic conditions that begin before birth or in early childhood, gene editing could make a huge difference in long-term health outcomes.

In the end, CRISPR represents a promising step toward a new type of medicine. While it cannot be used for preventative treatments yet, the progress shown in these sources suggests that

CRISPR could eventually become a key tool in stopping disease at the genetic level. Continued research, safer technology, strong ethics, and reliable funding will help determine how soon this future becomes reality.

Works Cited:

- “In First-of-Its-Kind Trial, Scientists Use CRISPR to Treat Cancer.” *Institute for Systems Biology*, 11 Nov. 2022, <https://isbscience.org/news/cancer/in-first-of-its-kind-trial-scientists-use-crispr-to-treat-cancer/>
- “Henderson, Hope. “CRISPR Clinical Trials: A 2026 Update.” *Innovative Genomics Institute*, 23 Mar. 2026. <https://innovativegenomics.org/news/crispr-clinical-trials-2026/>
- “Clinical Progress in Genome-Editing Technology and in Vivo Delivery Techniques.” *National Library of Medicine*, 2023, <https://pubmed.ncbi.nlm.nih.gov/36669950/>
- Cetin, Busra, et al. “Advancing CRISPR Genome Editing into Gene Therapy Clinical Trials: Progress and Future Prospects.” *Expert Reviews in Molecular Medicine*, vol. 27, 2025, e16. Cambridge University Press, 31 Mar. 2025. [Cambridge University Press article](#)
- “CRISPR – Engineering a Better Future through Genetics.” *SCOR*, 25 Apr. 2023, <https://www.scor.com/en/article/news-uk/crispr-engineering-better-future-through-genetics>